Background. It is unknown whether specific viral polymorphisms affect in vivo therapeutic response in patients with cytomegalovirus (CMV) disease. Polymorphisms in the CMV glycoprotein B (gB) gene allow discrimination of 4 distinct genotypes (gB1-gB4). We assessed the influence of gB genotypes on the clinical and virologic outcome of CMV disease.
viral virulence factors in the outcome of CMV infection [18] . One important viral target that has been previously investigated is glycoprotein B (gB) encoded by CMV UL55. gB has been implicated in several essential steps in CMV pathogenesis, such as virus entry, cell fusion, and cell-to-cell spread. In addition, gB is involved in the activation of innate immunity, is a major antigen for the induction of neutralizing antibodies, and plays a role in the induction of a cell-mediated immune response to CMV [19, 20] . Previous studies have shown that polymorphisms in the CMV UL55 gene (or gB gene) allow discrimination of 4 distinct genotypes (gB1-gB4) [21] . Investigation of associations between gB genotype and outcome have been inconsistent, with some studies indicating association with disease, and others showing no correlation with outcome [22, 23] . The aim of the present study was to assess the influence of the gB genotype on the outcome of CMV disease in a large, prospective cohort of patients included in a multicenter trial of CMV treatment (VICTOR study [A Study of Valcyte {Valgan-ciclovir} Compared with Ganciclovir in Patients with CMV Disease Who Are Solid Organ Transplant Recipients]) [24] .
METHODS

Patient population and definitions.
Solid-organ transplant recipients enrolled in a randomized, controlled trial of CMV disease treatment (VICTOR study) were included in this study. The results of the VICTOR study have been published elsewhere [24] . In brief, this randomized, open-label, multicenter, noninferiority trial compared treatment with oral valganciclovir to intravenous ganciclovir for CMV disease in solid-organ transplant recipients (ClinicalTrials.gov NCT00431353). Adult solidorgan transplant recipients with both virologic and clinical evidence of CMV disease were eligible for enrollment. Inclusion and exclusion criteria have been described previously [24] . The current study combined both treatment groups together and was planned a priori during the initial protocol design. A total of 321 patients were randomized into the treatment trial. Of these, 259 patients constituted the efficacy population (a positive central laboratory viremia assessment result at baseline). Antiviral treatment was administered for 21 days, followed by secondary prophylaxis with 900 mg daily (adjusted for kidney function) of valganciclovir until day 49.
CMV viral loads were determined in all patients at days 0, 3, 7, 10, 14, 17, 21, 28, 35, 42 , and 49 and then at months 3 and 6 after randomization and in the event of any symptom recurrence up to 12 months. Viral loads were measured in plasma at a central laboratory facility using the Amplicor CMV Monitor Test (Roche Diagnostics). For this substudy, treatment success was defined as viral eradication at day 21 using a viral load cutoff of 200 copies/mL (the lower limit of detection of the assay) by the Amplicor CMV Monitor Test. Recurrence of CMV DNAemia or clinical disease was defined as a positive polymerase chain reaction (PCR) result or clinical signs after eradication at day 49. The definition of CMV disease followed the guidelines of the American Society of Transplantation [25] . gB genotyping. Genotyping of gB was performed by quantitative real-time PCR on whole blood samples at day 0 (start of antiviral therapy) using methods previously described [26] . In brief, the primers and probes targeting the CMV gB1 to gB4 genes were designed with Primer Express (Applied Biosystems). Minor groove binding was used to enhance the specificity because the sequence of the gB gene is conserved. DNA was extracted from 200 mL of whole blood using the Qiagen blood mini kit. TaqMan PCR was performed with the ABI PRISM 7500 instrument with universal conditions. An external standard curve for the quantitation of gB genotypes was established with 10-fold serial dilutions of a 1500-base pair DNA fragment of the gB2 gene. The sensitivity of the TaqMan PCR was compared with a real-time LightCycler PCR assay used in the routine diagnostic laboratory with 10-fold serial dilutions of known gB1 to gB4 genotypes. To evaluate precision of the assay, 6 replicated TaqMan PCR reactions were run in 6 different days using 10-fold dilutions in 10 to 10 5 copies of DNA of each genotype (gB1 to gB4).
On the basis of the assay results for the baseline sample (day 0), patients were categorized as having infection with gB1, gB2, gB3, or gB4 or mixed infection. The latter was defined as CMV infection with 11 gB genotype in a single sample.
Statistical analysis. Given the results of the VICTOR study, which showed no differences between the treatment arms, we combined both groups for the analysis of the role of gB genotype in the outcome of CMV disease. Categorical variables were compared using the x 2 test. Continuous variables were compared using the t test or the Mann-Whitney U test in case of 2 samples and the 1-way analysis of variance or the Kruskal-Wallis test for multiple samples. Time to viral eradication was described using Kaplan-Meier survival analysis and compared within groups using the Breslow test (generalized Wilcoxon). A multivariable logistic regression or the CochranMantel-Haenszel test for the equality of the odds ratio was used to estimate the effect of gB genotype in a univariate and multivariate model adjusting for potential confounding factors, such as baseline plasma viral load (measured by Amplicor CMV Monitor), IgG levels at baseline, type of antiviral treatment received (valganciclovir or ganciclovir), and ganciclovir resistance. P values р.05 were considered to be statistically significant.
RESULTS
Patient population.
Among the 259 patients in the efficacy population with CMV disease in the VICTOR study, the gB genotype was available in 239 patients. The prevalence of gB strain types at day 0 was 26% (61 of 239) for gB1, 10% (23 of 239) for gB2, 10% (24 of 239) for gB3, 6% (13 of 239) for gB4, and 49% (118 of 239) for infection with more than 1 gB genotype (mixed infection) ( Figure 1 ).
), and all 4 genotypes ( ). Table 1 gives n p 35 n p 8 the baseline characteristics of the patients included in the study. No differences were found in terms of age, sex, antiviral treatment received, type of organ transplantation, and CMV serostatus between patients according to the gB genotype. However, significant differences were observed in the incidence of mixed infection on the basis of pretransplantation donor and recipient serotypes. D+/RϪ patients were more likely to be infected with a single genotype, whereas D+/R+ patients were more likely to be infected with a mixture of genotypes ( ). P ! .001 Characteristics of CMV disease according to gB genotype. The clinical and virologic characteristics of CMV disease are given in Table 2 . Overall, 136 (58%) of 235 patients had CMV viral syndrome and 99 (42%) of 235 patients had tissue-invasive disease. In 4 patients, the characteristics of CMV disease were (17) 5 (24) 2 (9) 2 (15) 19 (17) 13 (12) No 48 (83) 16 (76) 20 (91) 11 (85) 95 (83) 92 ( ). However, the overall P p .001 severity of CMV disease based on an assessment by the investigator was similar between groups.
Genotype and response to therapy. Whole-blood and plasma viral loads were analyzed and compared among different gB types (Table 2) . Median baseline viral loads in whole blood were higher in patients with mixed infection versus single gB infection (204,400 vs 74,150 copies/mL, ), whereas in P p .005 plasma elevated viral loads in patients with mixed gB genotypes was not significant (23,000 vs 14,000 copies/mL;
). Pa-P p .06 tients with gB3 genotype infection had higher viral load than patients with other genotype infections when measured in whole blood by real-time genotyping quantitative PCR (P p ) but not when measured by Amplicor plasma PCR ( .001 P p ). The mean ‫ע(‬ standard deviation) time to viral eradication . 22 was longer in mixed versus nonmixed infections ( vs 21.0 ‫ע‬ 2.6 days;
). In the univariate model, treatment 18.0 ‫ע‬ 1.1 P p .024 failure (defined by a lack of viral eradication at day 21) was higher in patients with mixed infection than in patients with infection with a single genotype (60.0% vs 41.5%;
). In P p .004 the multivariate model, mixed infection remained a significant predictor of failure of therapy (odds ratio, 2.66; 95% confidence interval, 1.31-5.38;
) after controlling for baseline viral P p .007 load, CMV serostatus at baseline, ganciclovir resistance, and antiviral treatment.
Complete information regarding clinical and virologic recurrence of CMV infection and disease was available for 219 of 239 patients. After initial therapy was completed, CMV disease recurrence was seen in 32 (14.6%) of 219 patients. No effect of gB genotype was seen on virologic or clinical CMV recurrence ( for mixed vs single genotype and P p .37 P p among the 4 different genotypes). .65
DISCUSSION
Although several previous studies have addressed the question of whether viral polymorphisms (especially polymorphisms of the gB gene) play a role in the outcome of CMV infection, the results of those studies have generally been inconclusive [22, 23, [27] [28] [29] . In part, this has been attributable to small sample sizes, retrospective studies, and/or heterogeneous treatment protocols. In the present study, we took advantage of the large number of solid-organ transplantation patients with CMV disease included in the VICTOR study to assess the frequency of mixed gB genotypes in this population, identify whether gB genotypes are associated with specific CMV disease entities, and determine whether gB genotypes influence the response to therapy with ganciclovir or valganciclovir.
Several conclusions can be made from the present study. First, we found that nearly one-half of the patients with CMV disease were infected with multiple genotypes simultaneously (mixed infection). Other studies have found a rate of mixed infection of 7%-26% [22, 23, 29] . The high rate of mixed infection in our study can perhaps be explained by the high sensitivity of the method used for the detection of the different gB genotypes (as low as 20 copies/mL) without any loss in specificity. This allowed us to discriminate mixed populations in which 1 genotype may be present in relatively low copy number. Second, we found that a higher rate of recipients with mixed infection had a pretransplantation D+/R+ serostatus, whereas D+/RϪ patients were more likely to have a single genotype infection. This is consistent with simultaneous reactivation of both donor and recipient CMV strains in D+/R+ patients. Moreover, the presence of mixed infection in a portion of D+/RϪ patients (12%) suggests that 11 genotype can also be simultaneously transmitted from the organ donor to the recipient [30] . The lower incidence of tissue-invasive disease in patients with mixed infection may reflect the role of mixed infection as a surrogate marker for seropositive recipients, a group that has been recognized to develop less tissue-invasive disease than D+/RϪ patients. However, the viral load was higher in patients with mixed infection. This may be due to difficulty in immunologic control of mixed viral strains that may require T cells that recognize different viral epitopes.
The risk factors for failure of antiviral therapy initially identified in the VICTOR study included a high baseline viral load and the presence of a lag phase (defined by failure to decrease viral load by ∼50% at 1 week) [24] . In the present study, we showed that mixed infection was an additional predictor for failure of antiviral therapy, independent of the baseline viral load, CMV serostatus, and resistance to ganciclovir. This is an intriguing finding, because mixed infection is mostly associated with seropositive recipients, the group that traditionally has a better response to antiviral therapy [31] .
The results of previous studies assessing the role of gB genotypes in CMV pathogenesis have been inconsistent. In a study involving 92 organ transplant recipients and patients with hematologic disease [22] , mixed infection was associated with higher baseline viral loads ( ) and in transplant recipients P ! .05 a higher rate of CMV disease and short-term rejection (P ! ). Consistent with our observations, no significant major .05 clinical or virologic differences have been found among individual genotypes in the latter study [22] . In another study [23] , there was a trend toward delayed viral clearance in patients with mixed infection ( ), although the sample size was n p 8 small (viral load half-life of 8.4 days for mixed infection, compared with 3.9 days for infection with a single genotype;
). Taken together, these data support the theory that P p .18 mixed infection may be more refractive to immunologic control compared with single gB genotype infections. Although gB participates in several essential steps for CMV pathogenesis, the reason why patients with mixed infection have an impaired response to antiviral therapy remains unexplained. Preexisting immunity in seropositive patients with mixed infection may only be epitope specific to the recipient strains but not to the donor-transmitted strains; therefore, the seropositive recipient acts as immunologically naive to the newly acquired strains [32] . Alternatively, gB genotype may be a surrogate marker for another as yet identified aspect of viral replicative fitness, such as polymorphisms in the CMV DNA polymerase UL54. We found that infection with gB3 had a higher baseline viral load, but no significant differences were found in the clinical characteristics of CMV disease or the response to antiviral therapy among individual gB genotypes.
This study had some limitations. It represents a secondary outcome analysis of the VICTOR study data and therefore was not the primary purpose of the study. However, this secondary analysis was specified a priori, thereby allowing for prospective gathering of appropriate samples and data. Although the large number of patients studied allowed us to build a robust multivariate analysis, we cannot exclude that the conclusions might have been biased by the presence of confounder variables not included in the model. On the other hand, strengths of the study include the large number of different solid-organ transplant recipients included from different parts of the world, the use of a sensitive and quantitative method for detecting the gB genotype, and an extensive and standardized follow-up to assess for the development of recurrent disease [24] . Therefore, many of the conclusions are robust and can be considered more definitive than possible with previous studies.
In summary, we analyzed the gB strain distribution in a large cohort of transplantation patients with CMV disease. Mixed genotype infection occurred in nearly one-half of the patients and was more likely if both donor and recipient were seropositive. Although no specific gB genotype appears to confer a specific viral virulence advantage, mixed infection was associated with higher viral loads and delayed virologic clearance, suggesting a potential role for viral polymorphisms in influencing in vivo viral fitness. Currently, it is unlikely that determination of infected genotypes will have significant clinical utility. However, this study provides important insight into the pathogenesis of CMV, and the nature of the immunologic response in patients with mixed strain infection should be explored in future studies.
